Penumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024. In the quarter to June 2026, revenue grew 14.9%, EPS fell 24.8%, free cash flow grew 10.8% and total debt fell 9.90%, each against the same quarter a year earlier. Revenue growth for ten consecutive years, operating cash flow growth for three.
Follow PEN
Penumbra, Inc. (PEN) EV/Sales
As of 16 October 2026, Penumbra, Inc. (PEN) trades at a EV/Sales of 8.0×. Over the past ten years it has ranged from 0.0× (September 2015) to 18.8× (April 2021); the current reading is higher than 32% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.2× | 11.24% |
| FY2024 | 7.4× | (14.08%) |
| FY2023 | 8.6× | (10.94%) |
| FY2022 | 9.7× | (29.92%) |
| FY2021 | 13.8× | 28.66% |
| FY2020 | 10.7× | 6.06% |
| FY2019 | 10.1× | 13.52% |
| FY2018 | 8.9× | 7.73% |
| FY2017 | 8.3× | 19.69% |
| FY2016 | 6.9× | 159.40% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.8× | (7.40%) |
| Mar 2026 | 8.5× | 2.57% |
| Dec 2025 | 8.2× | 16.40% |
| Sep 2025 | 7.1× | (5.16%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 1.5× |
| BRKR Bruker Corporation compare | 2.9× |
| ZBH Zimmer Biomet Holdings, Inc. compare | 3.0× |
| PODD Insulet Corporation compare | 3.3× |
| GMED Globus Medical, Inc. compare | 3.4× |
| BIO Bio-Rad Laboratories, Inc. compare | 3.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.6× |
| PEN Penumbra, Inc. | 8.0× |
| GKOS Glaukos Corporation compare | 15.9× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)